Fracture risk associated with chronic use of bisphosphonates: evidence today

Bibliography

• Torino RP, Meunier PJ, Emkey R, Phase III Osteoporosis Treatment Study Group. Skeletal benefits of alendronate:7-year treatment of postmenopausal osteoporotic women. J Clin Endocrinol Metab 2000;85:3109-15
   PubMed Web of Science ®Google Scholar
• Black DM, Thompson DE, Bauer DC, ; FIT Research Group. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture intervention Trial. J Clin Endocrinol Metab 2000;85:4118-24
   PubMed Web of Science ®Google Scholar
• Cummings SR, Black DM, Thompson D, Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. Results from the Fracture Intervention Trial. JAMA 1998;280:2077-82
   PubMed Web of Science ®Google Scholar
• Reginster J-Y, Minne H, Sorensen OH, Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000;11:83-91
   PubMed Web of Science ®Google Scholar
• McClung MR, Clemmesem B, Daifotis A, Alendronate prevents postmenopausal bone loss in women without osteoporosis. Ann Intern Med 1998;128:253-61
   PubMed Web of Science ®Google Scholar
• Fogelman I, Ribot C, Smith R, Risendronate reserves bone loss in postmenopausal women with low bone mass: results from a multi-national, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2002;85:1895-900
   Google Scholar
• Black DM, Schwartz A, Ensrud K, A 5 year randomized trial of the long-term efficacy and safety of alendronate. J Bone Miner Res 2004;10(Suppl 1):S45
   Google Scholar
• Black DM, Cummings SR, Karpf DB, Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41
   PubMed Web of Science ®Google Scholar
• Goh SK, Yang KY, Koh JS, Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 2007;89:349-53
   PubMed Web of Science ®Google Scholar
• Kwek EB, Goh SK, Koh JS, An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 2008;39:224-31
   PubMed Web of Science ®Google Scholar
• Neviaser AS, Lane JM, Lenart BA, Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 2008;22:346-50
   PubMed Web of Science ®Google Scholar
• Cheung RK, Leung KK, Lee KC, Chow TC. Sequential non-traumatic femoral shaft fractures in a patient on long term alendronate. Hong Kong Med J 2007;13:485-9
   PubMedGoogle Scholar
• Imai K, Yamamoto S, Anamizu Y, Horiuchi T. Pelvic insufficiency fracture associated with severe suppression of bone turnover by alendronate therapy. J Bone Miner Metab 2007;25:333-6
   PubMed Web of Science ®Google Scholar
• Odvina CV, Levy S, Rao S, Unusual mid-shaft fractures during long-term bisphosphonate therapy. Clin Endocrinol (Oxf) 2010;72:161-8
   PubMed Web of Science ®Google Scholar
• Somford MP, Draijer FW, Thomassen BJ, Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long term treatment with alendronate: clues to the mechanism of increased bone fragility. J Bone Miner Res 2009;24:1736-40
   PubMed Web of Science ®Google Scholar
• Boivin G, Farlay D, Bala Y, Influence of remodeling on the mineralization of bone tissue. Osteoporos Int 2009;20:1023-6
   PubMed Web of Science ®Google Scholar
• Allen MR, Reinwald S, Burr DB. Alendronate reduces bone toughness of ribs without significantly increasing microdamage accumulation in dogs following 3 years of daily treatment. Calcif Tissue Int 2008;82:354-60
   PubMed Web of Science ®Google Scholar
• Mashiba T, Turner CH, Hirano T, Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001;28:524-31
   PubMed Web of Science ®Google Scholar
• Weinstein RS. True strength. J Bone Miner Res 2000;15:621-5
   PubMed Web of Science ®Google Scholar
• Watts NB. Bisphosphonate treatment for osteoporosis. In: Avioli LV, editor, The osteoporotic syndrome. Academic Press, San Diego; 2000. p. 121-32
   Google Scholar
• Kavanagh KL, Guo K, Dunford JE, The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci USA 2006;103:7829-34
   PubMed Web of Science ®Google Scholar
• Hughes DE, Wright KR, Uy HL, Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995;10:1478-87
   PubMed Web of Science ®Google Scholar
• Frith JC, Monkkonen J, Blackburn GM, Clondronate and liposome-encapsulated clondronate are metabolized to a toxic ATP analog, adenosine 5′(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 1997;12:1358-67
   PubMed Web of Science ®Google Scholar
• Kimmel DB. Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res 2007;86:1022-33
   PubMed Web of Science ®Google Scholar
• Russell RGG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008;19:733-59
   PubMed Web of Science ®Google Scholar
• Watts NB, Diab DL. Long-term use of bisphosphonates in Osteoporosis. J Clin Endocrinol Metab 2010;95:1555-65
   PubMed Web of Science ®Google Scholar
• Chesnut C III, Skag A, Christiansen C, Effects of oral ibandronate administrated daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-9
   PubMed Web of Science ®Google Scholar
• Harris ST, Watts NB, Genant HK, Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-52
   PubMed Web of Science ®Google Scholar
• McClung MR, Geusens P, Miller PD, Zippel H, ; for the Hip Intervention Program (HIP) Study Group. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344:333-40
   PubMed Web of Science ®Google Scholar
• Black DM, Delmas PD, Eastell R, Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22
   PubMed Web of Science ®Google Scholar
• McClung MR, Wasnich RD, Hosking DJ, Prevention of postmenopausal bone loss: six year results from the early postmenopausal intervention cohort study. J Clin Endocrinol Metab 2004;89:4879-85
   PubMed Web of Science ®Google Scholar
• Wasnich RD, Bagger YZ, Hosking DJ, Changes in bone density and turnover after alendronate or estrogen withdrawal. Menopause 2004;11:622-30
   PubMedGoogle Scholar
• Bone HG, Hosking D, Devogelaer J-P, Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-99
   PubMed Web of Science ®Google Scholar
• Black DM, Schwartz AV, Ensrud KE, Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;296:2927-38
   PubMed Web of Science ®Google Scholar
• Mellstrom DD, Sorensen OH, Goemaere S, Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004;75:462-8
   PubMed Web of Science ®Google Scholar
• Schwartz AV, Bauer DC, Cumming SR, Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res 2010;25:976-82
   PubMed Web of Science ®Google Scholar
• Breglia MD, Carter JD. Atypical insufficiency fracture of the tibia associated with long-term bisphosphonate therapy. J Clin Rheumatol 2010;16:76-8
   PubMed Web of Science ®Google Scholar
• Lee P, van der Wall H, Seibel MJ. Looking beyond low bone mineral density: multiple insufficiency fractures in a woman with post-menopausal osteoporosis on alendronate therapy. J Endocrinol Invest 2007;30:590-7
   PubMed Web of Science ®Google Scholar
• Armamento-Villareal R, Napoli N, Panwar V, Suppressed bone turnover during alendronate therapy, for high-turnover osteoporosis. N Engl J Med 2006;355:2048-50
   PubMed Web of Science ®Google Scholar
• Schneider JP. Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate. Geriatrics 2006;61:31-3
   PubMed Web of Science ®Google Scholar
• Demiralp B, Ilgan S, Ozgur Karacalioglu A, Bilateral femoral insufficiency fractures treated with inflatable intramedullary nails: a case report. Arch Orthop Trauma Surg 2007;127:597-601
   PubMed Web of Science ®Google Scholar
• Kumm DA, Rack C, Rutt J. Subtrochanteric stress fracture of the femur following total knee arthroplasty. J Arthroplasty 1997;12:580-3
   PubMed Web of Science ®Google Scholar
• Husada G, Libbeerecht K, Peeters T, Populaire J. Bilateral middiaphyseal femoral stress fractures in the elderly. Eur J Trauma 2005;35:68-71
   Google Scholar
• Ing-Lorenzini K, Desmeules J, Plachta O, Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital. Drug Saf 2009;32:775-85
   PubMed Web of Science ®Google Scholar
• Odvina CV, Zerwekh JE, Rao DE, Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294-301
   PubMed Web of Science ®Google Scholar
• Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008;358:1304-6
   PubMed Web of Science ®Google Scholar
• Visekruna M, Wilson D, McKiernan FE. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 2008;93:2948-52
   PubMed Web of Science ®Google Scholar
• Capeci CM, Tejwani NC. Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J Bone Joint Surg Am 2009;91:2556-61
   PubMed Web of Science ®Google Scholar
• Lenart BA, Neviaser AS, Lyman S,Chang CC, Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 2009;20:1353-62
   PubMed Web of Science ®Google Scholar
• Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 2009;24:1095-102
   PubMed Web of Science ®Google Scholar
• Schilcher J, Aspenberg P. Incidence of stress fractures of femoral shaft in women treated with bisphosphonate. Acta Orthop 2009;80:413-15
   PubMed Web of Science ®Google Scholar
• Black DM, Kelly MP, Genant HK, Fracture Intervention Trial steering committee, and HORIZON Pivotal Fracture Trial Steering Committee. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 2010;362(19):1761-71
   PubMed Web of Science ®Google Scholar
• Armamento-Villareal R, Napoli N, Diemer K, Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates; a case series. Calcif Tissue Int 2009;85:37-44
   PubMed Web of Science ®Google Scholar
• Ensrud KE, Barrett-Connor EL, Schwartz A, Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res 2004;19:1259-69
   PubMed Web of Science ®Google Scholar
• Allen MR, Burr DB. Skeletal microdamage: less about biomechanics and more about remodeling. Clin Rev Bone Miner Metab 2008;6:24-30
   Google Scholar
• Garrison JG, Slaboch CL, Niebur GL. Density and architecture have greater effects on the toughness of trabecular bone than damage. Bone 2009;44:924-9
   PubMed Web of Science ®Google Scholar
• Abrahamsen B. Adverse effects of bisphosphonates. Calcif Tissue Int 2010;86:421-35
   PubMed Web of Science ®Google Scholar
• Nieves JW, Bilezikian JP, Lane JM, Fragility fractures of hip and femur: incidence and patient characteristics. Osteoporos Int 2010;21:399-408
   PubMed Web of Science ®Google Scholar